Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.55 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283589 | 1.00 | CNR2 (0.59) | CNR2CHRNB2CHRNA4CHRNA7CHRNA5 | |
| SCHEMBL283146 | 0.92 | CNR2 (0.59) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL283145 | 0.92 | CNR2 (0.59) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL283562 | 0.90 | CNR2 (0.59) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL283563 | 0.90 | CNR2 (0.59) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL286122 | 0.89 | CNR2 (0.60) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL286123 | 0.89 | CNR2 (0.60) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL1974220 | 0.88 | CNR2 (0.59) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL1974225 | 0.88 | CNR2 (0.59) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL3627815 | 0.88 | CNR2 (0.59) | CNR2CHRNB2CHRNB1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885CHRNB2 206/4885CHRNA4 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.